Details of the Drug

General Information of Drug (ID: DM02AWV)

Drug Name

Tolbutamide

Synonyms

Aglicid; Arcosal; Arkozal; Artosin; Artozin; Beglucin; Butamid; Butamide; Butamidum; Diaben; Diabesan; Diabetamid; Diabetol; Diabuton; Diasulfon; Diaval; Dirastan; Dolipol; Drabet; Glyconon; Ipoglicone; Mobenol; Orabet; Oralin; Oramide; Orezan; Orinase; Orinaz; Oterben; Pramidex; Rastinon; Restinon; Tarasina; Tolbet;Tolbusal; Tolbutamid; Tolbutamida; Tolbutamidum; Tolbutone; Toluina; Tolumid; Toluran; Toluvan; Tolylsulfonylbutylurea; Willbutamide; Apotex Brand of Tolbutamide; Aventis Brand of Tolbutamide; BerlinChemie Brand of Tolbutamide; Butamide Brand of Tolbutamide; Hoechst Brand of Tolbutamide; Pfizer Brand of Tolbutamide; TOLBUTAMIDE USP; Tolbutamide Aventis Brand; Tolbutamide Butamide Brand; Tolbutamide Hoechst Brand; Tolbutamide Pfizer Brand; Valdecasas Brand of Tolbutamide; Yamanouchi Brand of Tolbutamide; D 860; HLS 831; T 0891; U 2043; Apo-Tolbutamide; Berlin-Chemie Brand of Tolbutamide; Novo-Butamide; Orinase (TN); Sk-tolbutamide; Tol-Tab; Tolbutamida [INN-Spanish]; Tolbutamidum [INN-Latin]; Tolbutamide [INN:BAN:JAN]; R.A.N. Brand of Tolbutamide; Tolbutamid R.A.N.; Tolbutamide (JP15/USP/INN); N-4-Methylbenzolsulfonyl-N-butylurea; N-4-(Methylbenzolsulfonyl)-n-butylurea; N-Butyl-N'-p-toluenesulfonylurea; N-n-Butyl-N'-tosylurea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-(p-Tolylsulfonyl)-N'-butylcarbamide; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; N-(p-tolylsulfonyl)-N'-n-butylurea; 1-Butyl-3-(4-methylphenylsulfonyl)urea; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-Butyl-3-(p-tolylsulfonyl)urea; 1-Butyl-3-(para-tolylsulfonyl) urea; 1-Butyl-3-tosylurea; 1-butyl-3-(4-methylphenyl)sulfonylurea; 1-p-Toluenesulfonyl-3-butylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; 3-(p-tolylsulfonyl)-1-butylurea; 3-[p-Tolyl-4-sulfonyl]-1-butylurea

Indication

Disease Entry	ICD 11	Status	REF
Non-insulin dependent diabetes	5A11	Approved	[1]

Therapeutic Class

Hypoglycemic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

270.35

Topological Polar Surface Area (xlogp)

2.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability: 85% of drug becomes completely available to its intended biological destination(s) [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 0.21 mL/min/kg [4]
Elimination: 0% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 7 hours [4]
Metabolism: The drug is metabolized via the liver [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 123.17236 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.05% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.12 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.109 mg/mL [2]

Chemical Identifiers

Formula: C12H18N2O3S
IUPAC Name: 1-butyl-3-(4-methylphenyl)sulfonylurea
Canonical SMILES: CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C
InChI: InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)
InChIKey: JLRGJRBPOGGCBT-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5505
ChEBI ID: CHEBI:27999
CAS Number: 64-77-7
DrugBank ID: DB01124
TTD ID: D06OIV
VARIDT ID: DR00104
INTEDE ID: DR1612
ACDINA ID: D00685

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ATP-binding cassette transporter C8 (ABCC8)	TTP835K	ABCC8_HUMAN	Blocker	[7]
ATP-binding cassette transporter C9 (ABCC9)	TTEF5MJ	ABCC9_HUMAN	Blocker	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sulfonylurea receptor 1 (ABCC8)	DTI58LU	ABCC8_HUMAN	Substrate	[8]
Sulfonylurea receptor 2 (ABCC9)	DT3JCE6	ABCC9_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[9]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[10]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[11]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Non-insulin dependent diabetes

ICD Disease Classification

5A11

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
ATP-binding cassette transporter C9 (ABCC9)	DTT	ABCC9	6.51E-01	0.02	0.06
ATP-binding cassette transporter C9 (ABCC9)	DTT	ABCC9	8.46E-01	0.02	0.22
Sulfonylurea receptor 1 (ABCC8)	DTP	SUR1	2.48E-02	1.04E-01	3.79E-01
Sulfonylurea receptor 1 (ABCC8)	DTP	SUR1	6.55E-02	1.00E-01	4.41E-01
Sulfonylurea receptor 2 (ABCC9)	DTP	SUR2	6.51E-01	2.26E-02	6.23E-02
Sulfonylurea receptor 2 (ABCC9)	DTP	SUR2	8.46E-01	2.42E-02	2.17E-01
Cytochrome P450 2C18 (CYP2C18)	DME	CYP2C18	8.28E-05	1.33E-01	1.20E+00
Cytochrome P450 2C18 (CYP2C18)	DME	CYP2C18	1.51E-03	-1.83E-01	-2.01E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	2.41E-01	3.17E-02	2.29E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	5.67E-01	5.11E-02	1.35E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	4.79E-03	1.32E-01	7.85E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	1.82E-01	-1.71E-02	-9.86E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	7.33E-02	5.59E-02	2.99E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	5.65E-03	-7.28E-02	-1.24E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tolbutamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Tolbutamide due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[52]
Tromethamine	DMOBLGK	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Tolbutamide caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[53]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Tolbutamide caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[54]
Oxymetholone	DMFXUT8	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Oxymetholone.	Aplastic anaemia [3A70]	[55]
Clarithromycin	DM4M1SG	Moderate	Increased plasma concentration of Tolbutamide and Clarithromycin due to competitive binding of plasma proteins.	Bacterial infection [1A00-1C4Z]	[56]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Tolbutamide caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[57]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[58]
Anisindione	DM2C48U	Moderate	Increased plasma concentration of Tolbutamide and Anisindione due to competitive binding of plasma proteins.	Coagulation defect [3B10]	[59]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Tolbutamide caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[60]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Tolbutamide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[61]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Tolbutamide caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[62]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Vortioxetine.	Depression [6A70-6A7Z]	[58]
Isocarboxazid	DMAF1NB	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Isocarboxazid.	Depression [6A70-6A7Z]	[58]
Escitalopram	DMFK9HG	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Escitalopram.	Depression [6A70-6A7Z]	[58]
SODIUM CITRATE	DMHPD2Y	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Tolbutamide caused by SODIUM CITRATE mediated altered urine pH.	Discovery agent [N.A.]	[53]
Brivaracetam	DMSEPK8	Minor	Decreased metabolism of Tolbutamide caused by Brivaracetam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[54]
Sulfinpyrazone	DMEV954	Moderate	Decreased metabolism of Tolbutamide caused by Sulfinpyrazone.	Gout [FA25]	[63]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Tolbutamide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[64]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Tolbutamide caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Captopril	DM458UM	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Captopril.	Hypertension [BA00-BA04]	[58]
Sodium acetate anhydrous	DMH21E0	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Tolbutamide caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[53]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Tolbutamide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[66]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Hydroxychloroquine.	Malaria [1F40-1F45]	[58]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Sulphadoxine.	Malaria [1F40-1F45]	[55]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Tolbutamide caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[66]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Tolbutamide caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[66]
Mecasermin	DM1O3BY	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Mecasermin.	Multiple structural anomalies syndrome [LD2F]	[58]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Tolbutamide caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[54]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Tolbutamide caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[67]
Rasagiline	DM3WKQ4	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Rasagiline.	Parkinsonism [8A00]	[58]
Choline salicylate	DM8P137	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[55]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Tolbutamide caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[68]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Tolbutamide caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[69]
Salsalate	DM13P4C	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Salsalate.	Rheumatoid arthritis [FA20]	[58]
Ifosfamide	DMCT3I8	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[58]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[58]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Tolbutamide due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[67]
Pramlintide	DM0EZ9Q	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Pramlintide.	Type-1/2 diabete [5A10-5A11]	[58]
Olsalazine	DMZW9HA	Moderate	Increased risk of hypoglycemia by the combination of Tolbutamide and Olsalazine.	Ulcerative colitis [DD71]	[58]
-----------


⏷ Show the Full List of 39 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tolbutamide 500 mg tablet	500 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	BDDCS applied to over 900 drugs
3	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90.
8	ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 2007 Feb;453(5):703-18.
9	Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos. 2001 Feb;29(2):141-4.
10	CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos. 2000 Mar;28(3):354-9.
11	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
12	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
14	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
15	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
16	Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
17	Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
18	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
19	Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
20	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
21	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
22	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
23	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
24	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
25	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
26	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
27	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
28	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
29	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
30	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
31	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
32	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
33	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
34	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
35	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
36	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
37	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
38	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
39	Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
40	Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8.
41	A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) chann... J Mol Cell Cardiol. 2005 Jul;39(1):1-6.
42	BTS-67582 (Knoll Pharmaceuticals Co). IDrugs. 1999 Apr;2(4):355-9.
43	Effects of KRN2391 on ionic currents in rabbit femoral arterial myocytes
44	Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K+ (K(ATP)) channels by Mg-nucleotides. J Physiol. 2003 Feb 15;547(Pt 1):159-68.
45	The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats.J Cereb Blood Flow Metab.2007 Feb;27(2):348-55.
46	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
47	Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72.
48	Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9.
49	Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats.Metabolism.2004 Apr;53(4):441-7.
50	Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
51	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2944).
52	Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80. [PMID: 1623912]
53	Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6. [PMID: 1646724]
54	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
55	Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
56	Bussing R, Gende A "Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction." Diabetes Care 25 (2002): 1659-61. [PMID: 12196446]
57	Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
58	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
59	Hansen JM, Christensen LK "Drug interactions with oral sulphonylurea hypoglycaemic drugs." Drugs 13 (1977): 24-34. [PMID: 401727]
60	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
61	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
62	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
63	Mahfouz M, Abdel-Maguid R, El-Dakhakhny M "Potentiation of the hypoglycaemic action of tolbutamide by different drugs." Arzneimittelforschung 20 (1970): 120-2. [PMID: 5467602]
64	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
65	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
66	Cerner Multum, Inc. "Australian Product Information.".
67	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
68	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
69	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]